FIELD: medicine, pharmaceutics.
SUBSTANCE: present invention refers to compounds of formula
,
using them as tubulin polymerisation inhibitors and PARP inhibitors, and also as an ingredient of pharmaceutical compositions containing the above compounds of formula (I), wherein R1, R2, R3, R4, R5, R6, R7 and Y have the values specified in the patent claim.
EFFECT: preparing intermediate compounds for preparing the compounds of formula (I) and a method for preparing the intermediate compounds.
16 cl, 3 tbl, 40 ex
Title | Year | Author | Number |
---|---|---|---|
MDM2 AND P53 INTERACTION INHIBITORS | 2007 |
|
RU2436784C2 |
PYRIDAZINONE DERIVATIVES AS PARP INHIBITORS | 2008 |
|
RU2490265C2 |
SUBSTITUTED QUINAZINE DERIVATIVES AS FGFR-KINASE INHIBITORS FOR TREATMENT OF CANCER | 2011 |
|
RU2602233C2 |
COMPOUNDS AND COMPOSITIONS AS CANAL ACTIVATING PROTEASE INHIBITORS | 2007 |
|
RU2419625C2 |
ANTI-CANCER BENZOPYRAZINES ACTING THROUGH FGFR-KINASES INHIBITION | 2012 |
|
RU2639863C2 |
POLY(ADP-RIBOSE)POLYMERASE INHIBITOR PRODUCTION METHOD | 2005 |
|
RU2344138C2 |
MDM2 AND P53 INTERACTION INHIBITORS | 2008 |
|
RU2477724C2 |
SUBSTITUTED AMINOBUTYRIC DERIVATIVES AS NEPRILYSIN INHIBITORS | 2012 |
|
RU2604522C2 |
PTERIDINES AS FGFR INHIBITORS | 2013 |
|
RU2702906C2 |
IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES | 2009 |
|
RU2518089C2 |
Authors
Dates
2013-08-20—Published
2009-03-26—Filed